Harbin Pharmaceutical Co., Ltd. announced that recently its subsidiary Harbin Pharmaceutical Biotech received the Potassium Sulfate “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the State Drug Administration. Potassium sulfate is one of the raw materials for oral administration of a concentrated solution of magnesium, sodium, and potassium sulfate. As of the announcement date, there were 26 domestic companies with a “A” registration status for potassium sulfate raw materials. The company has invested about 631,500 yuan in R&D expenses for this project. This approval will consolidate the company's integrated strategy of raw materials and formulation and enrich the product pipeline, but production and sales of APIs are affected by various factors, and there is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.